
|Slideshows|April 4, 2018
sTMS Device May Prevent Migraine
Author(s)Veronica Hackethal, MD
A study undertaken to evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine has led to an FDA extended indication.
Advertisement
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
4
Reinforce Ocrelizumab’s Role Across the Full Spectrum of More Advanced Progressive MS: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
5